dentsu health Merges Antibody into Canadian Business
April 28, 2022
Dentsu Canada announced that ANTIBODY Healthcare Communications will merge into dentsu health as part of a global consolidation to officially launch and scale dentsu health in the Canadian market. The move integrates Antibody’s medical and science communications capabilities with dentsu health’s global healthcare offering to strengthen dentsu’s healthcare marketing, digital, social and influencer services.
- Buyers
- dentsu health, Dentsu Canada
- Targets
- ANTIBODY Healthcare Communications
- Industry
- Marketing & Advertising
- Location
- Ontario, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Takeda Acquires Adaptate Biotherapeutics
January 10, 2022
Biotechnology
Takeda Pharmaceutical Company Limited has exercised its option to acquire Adaptate Biotherapeutics, a UK biotechnology spin-out focused on antibody-based γδ T cell engager therapies for solid tumors. The acquisition gives Takeda Adaptate’s antibody-based γδ T cell engager platform and preclinical pipeline to strengthen Takeda’s immuno-oncology capabilities and accelerate development of Vδ1‑targeting therapies.
-
Atlas Antibodies Acquires HistoCyte Laboratories Ltd
February 1, 2021
Medical Devices
Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
SERB Pharmaceuticals Acquires Y-mAbs Therapeutics
September 16, 2025
Biotechnology
SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.
-
DAS Health Acquires North American Digital Health Division from Canadian Provider
July 9, 2024
Healthcare Services
DAS Health Ventures (a Sheridan Capital Partners portfolio company) acquired the North American Digital Health division of an established Canadian digital transformation provider, giving DAS Health a footprint in Canada and expanding its senior care-focused health IT capabilities. The division adds managed IT, cybersecurity, cloud hosting, integrations, and revenue cycle management services to DAS Health's offerings as an add-on to its existing platform.
-
Dentsu Group Acquires Tag from Advent International
March 7, 2023
Marketing & Advertising
Dentsu Group Inc. has agreed to acquire Tag, a global omnichannel marketing production company, from private equity firm Advent International. Tag, which operates a proprietary marketing execution platform (Digital Interact) and employs ~2,800 people across 29 countries, will become part of dentsu's network to expand its content production and technology-enabled marketing capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.